Advances in Treatment for Metastatic Hormone Sensitive Prostate Cancer: With So Many Options, Can We Really Go Wrong?
www.urotoday.com/center-of-excellence/mhspc/from-the-editor/114565-advances-in-treatment-for-metastatic-hormone-sensitive-prostate-cancer-mhspc-with-so-many-options-can-we-really-go-wrong.html
Jan 20, 2021
3
Impact of Academic Collaborations in mHSPC Trial: ENZAMET - Chris Sweeney
www.urotoday.com/video-lectures/asco-2019/video/1324-impact-of-academic-collaborations-in-mhspc-trial-enzamet-chris-sweeney.html
Jan 20, 2021
11
ASCO GU 2020: Treatment Selection in mHSPC: Considerations Now and Downstream in an Evolving Therapeutic Landscape
www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-prostate-cancer/119166-asco-gu-2020-treatment-selection-in-cspc-considerations-now-and-downstream-in-an-evolving-therapeutic-landscape-discussion-of-abstracts-82-and-162.html
Jan 20, 2021
5
Ileal Conduit Versus Cutaneous Ureterostomy After Radical Cystectomy - Full Text View - ClinicalTrials.gov
clinicaltrials.gov/ct2/show/NCT04610385
Jan 17, 2021
1
ASCO 2020: HERO Phase III Trial: Results Comparing Relugolix, an Oral GnRH Receptor Antagonist, versus Leuprolide Acetate for Advanced Prostate Cancer
www.urotoday.com/conference-highlights/asco-2020/asco-2020-prostate-cancer/121804-asco-2020-hero-phase-iii-trial-results-comparing-relugolix-an-oral-gnrh-receptor-antagonist-versus-leuprolide-acetate-for-advanced-prostate-cancer.html
Jan 17, 2021
1
ASCO GU 2020: Efficacy of Olaparib by Prior Taxane Use in Patients with Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Repair Gene Alterations: The PROfound Trial
www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-prostate-cancer/119414-asco-gu-2020-profound-efficacy-of-olaparib-by-prior-taxane-use-in-patients-with-metastatic-castration.html
Jan 9, 2021
1
SUO 2020: Results from the PROfound Study, A New Second Line Therapy for mCRPC
www.urotoday.com/conference-highlights/suo-2020/suo-2020-gu-malignancies-prostate/126345-suo-2020-results-from-the-profound-study-a-new-second-line-therapy-for-mcrpc.html
Jan 9, 2021
6
PI-RADS 2.1 - Image Interpretation: The Most Important Updates and Their Clinical Implications.
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/126809-pi-rads-2-1-image-interpretation-the-most-important-updates-and-their-clinical-implications.html
Dec 25, 2020
3
Clinical impact of PSMA PET in biochemically recurrent prostate cancer; a review of the literature
link.springer.com/article/10.1007/s13629-020-00296-6
Dec 23, 2020
1
Treatment Outcomes from 68Ga-PSMA PET/CT–Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET
scite.ai/reports/treatment-outcomes-from68ga-psma-pet-ct-informed-salvage-vJGwdZ4
Dec 23, 2020
1
APCCC 2019: How to Treat Men with Newly Diagnosed cN1 cM0 Prostate Cancer - Surgery Options
www.urotoday.com/conference-highlights/apccc-2019/114595-apccc-2019-how-to-treat-men-with-newly-diagnosed-cn1-cm0-prostate-cancer-surgery-options.html
Dec 20, 2020
4
FDA Approves First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer
www.fda.gov/news-events/press-announcements/fda-approves-first-psma-targeted-pet-imaging-drug-men-prostate-cancer
Dec 19, 2020
1
ASCO GU 2020: Challenging Cases in Prostate Cancer – Case 1: PSMA PET/CT Imaging
www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-prostate-cancer/119153-asco-gu-2020-challenging-cases-in-prostate-cancer-case-1.html
Dec 18, 2020
1
The Impact of Adding Sentinel Node Biopsy to Extended Pelvic Lymph Node Dissection on Biochemical Recurrence in Prostate Cancer Patients Treated with Robot-Assisted Radical Prostatectomy
jnm.snmjournals.org/content/59/2/204
Dec 18, 2020
2
RESTORE: A single-arm, open-label phase II trial of bipolar androgen therapy (BAT) in men with metastatic castration resistant prostate cancer (mCRPC)—A comparison of post-abiraterone (Abi) versus post-enzalutamide (Enza) patients (Pts). | Journal of Clinical Oncology
ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.5576
Nov 22, 2020
1
RESTORE: A single-arm, open-label phase II trial of bipolar androgen therapy (BAT) in men with metastatic castration resistant prostate cancer (mCRPC)—A comparison of post-abiraterone (Abi) versus post-enzalutamide (Enza) patients (Pts). | Journal of Clinical Oncology
ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.5576?af=R
Nov 22, 2020
1
Accuracy of 68Ga-PSMA-11 for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: A multicenter prospective phase III imaging study. | Journal of Clinical Oncology
ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.5502
Nov 9, 2020
2
Extended versus limited pelvic lymphadenectomy during radical prostatectomy for intermediate- and high-risk prostate cancer: Early outcomes from a randomized controlled phase III study. | Journal of Clinical Oncology
ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.5018
Nov 7, 2020
1
EAU 2020: Continence Following Robot-Assisted and Conventional Laparoscopic Radical Prostatectomy– Results of a Prospective, Randomized, Multicenter, Patient Blinded Study
www.urotoday.com/conference-highlights/eau-2020/prostate-cancer/123156-eau-2020-continence-following-robot-assisted-and-conventional-laparoscopic-radical-prostatectomy-results-of-a-prospective-randomized-multicenter-patient-blinded-study.html
Nov 6, 2020
1
Non-muscle Invasive Bladder Cancer: Overcoming Diagnostic and Therapeutic Challenges
www.urotoday.com/journal/everyday-urology-oncology-insights/articles/125180-non-muscle-invasive-bladder-cancer-overcoming-diagnostic-and-therapeutic-challenges.html
Nov 1, 2020
3
The Evolving Role of Prostate-Specific Membrane Antigen–Based Diagnostics and Therapeutics in Prostate Cancer | American Society of Clinical Oncology Educational Book
ascopubs.org/doi/10.1200/EDBK_239187
Oct 31, 2020
2
The Evolving Role of Prostate-Specific Membrane Antigen–Based Diagnostics and Therapeutics in Prostate Cancer | American Society of Clinical Oncology Educational Book
ascopubs.org/doi/10.1200/EDBK_239187?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
Oct 31, 2020
2
Treatment Outcomes from 68Ga-PSMA PET/CT–Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET
jnm.snmjournals.org/content/58/12/1972.long
Oct 30, 2020
1
Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial.
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/123841-pelvic-lymph-node-staging-with-18f-dcfpyl-pet-ct-prior-to-extended-pelvic-lymph-node-dissection-in-primary-prostate-cancer-the-salt-trial.html
Oct 26, 2020
1
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer | NEJM
www.nejm.org/doi/10.1056/NEJMoa022148
Oct 20, 2020
3
The Zettelkasten Method: Examples to help you get started.
medium.com/@rebeccawilliams9941/the-zettelkasten-method-examples-to-help-you-get-started-8f8a44fa9ae6
Oct 10, 2020
1
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
www.cell.com/cell/fulltext/S0092-8674(17)31056-5
Oct 9, 2020
1
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
www.cell.com/cell/fulltext/S0092-8674(17)31056-5?_returnURL=https://linkinghub.elsevier.com/retrieve/pii/S0092867417310565?showall=true
Oct 9, 2020
1
Lynch Syndrome
www.cancer.net/cancer-types/lynch-syndrome
Oct 5, 2020
4
Lynch Syndrome | CDC
www.cdc.gov/genomics/disease/colorectal_cancer/lynch.htm
Oct 5, 2020
3
Study simplifies bladder cancer molecular subtypes
www.mdedge.com/hematology-oncology/article/214920/genitourinary-cancer/study-simplifies-bladder-cancer-molecular
Oct 3, 2020
1
Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care?
www.ncbi.nlm.nih.gov/pmc/articles/PMC3553558/
Aug 28, 2020
1
EAU 2020: Perioperative Therapy for Urothelial Cancer: Should We Sequence All Urothelial Cancer Patients?
www.urotoday.com/conference-highlights/eau-2020/bladder-cancer/123221-eau-2020-perioperative-therapy-for-urothelial-cancer-should-we-sequence-all-urothelial-cancer-patients.html
Aug 1, 2020
10
EAU 2020: Frailty and Cognitive Assessment in Patients Diagnosed with Muscle-Invasive Bladder Cancer
www.urotoday.com/conference-highlights/eau-2020/bladder-cancer/123173-eau-2020-frailty-and-cognitive-assessment-in-patients-diagnosed-with-muscle-invasive-bladder-cancer.html
Aug 1, 2020
6
EAU 2020: Different Bladder Cancer Genotypes: New Treatment Options
www.urotoday.com/conference-highlights/eau-2020/bladder-cancer/123177-eau-2020-different-bladder-cancer-genotypes-new-treatment-options.html
Jul 29, 2020
1
EAU 2020: Perioperative Therapy for Urothelial Cancer: Should We Sequence All Urothelial Cancer Patients?
www.urotoday.com/conference-highlights/eau-2020/bladder-cancer/123221-eau-2020-perioperative-therapy-for-urothelial-cancer-should-we-sequence-all-urothelial-cancer-patients.html
Jul 29, 2020
7
EAU 2020: Recurrence Risk in Patients with High Grade Non-Muscle Invasive Bladder Carcinoma in the Randomised Phase III Clinical Trial ‘NIMBUS’ Stratified for EORTC and CUETO Risk Categories. A contemporary Trend to Less Recurrences?
www.urotoday.com/conference-highlights/eau-2020/bladder-cancer/123165-eau-2020-recurrence-risk-in-patients-with-high-grade-non-muscle-invasive-bladder-carcinoma-in-the-randomised-phase-iii-clinical-trial-nimbus-stratified-for-eortc-and-cueto-risk-categories-a-contemporary-trend-to-less-recurrences.html
Jul 27, 2020
2
EAU 2020: Early Cystectomy in High-Risk Non-Muscle Invasive Bladder Cancer: A Standard
www.urotoday.com/conference-highlights/eau-2020/bladder-cancer/123162-eau-2020-early-cystectomy-in-high-risk-non-muscle-invasive-bladder-cancer-a-standard.html
Jul 22, 2020
17
PARP Inhibitors in Prostate Cancer
www.urotoday.com/library-resources/advanced-prostate-cancer/122683-parp-inhibitors-in-prostate-cancer.html
Jul 5, 2020
2
ESMO 2019: Homogenizing Genomic Reports: What Clinicians Need to Know
www.urotoday.com/conference-highlights/esmo-2019/esmo-2019-prostate-cancer/115340-esmo-2019-homogenizing-genomic-reports-what-clinicians-need-to-know.html
Apr 11, 2020
1
EAU 2019: Rare Histological Variants of Prostate Adenocarcinoma: A National Cancer Database (NCDB) Analysis
www.urotoday.com/conference-highlights/eau-annual-congress-2019/eau-2019-prostate-cancer/110924-eau-2019-rare-histological-variants-of-prostate-adenocarcinoma-pca-a-national-cancer-database-ncdb-analysis.html
Apr 11, 2020
3
Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer.
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/118197-transcriptomic-heterogeneity-of-androgen-receptor-activity-defines-a-de-novo-low-ar-active-subclass-in-treatment-naive-primary-prostate-cancer.html
Apr 11, 2020
2
Primary Tumors Can Tell Us More If We Ask Them To
www.urotoday.com/center-of-excellence/mcrpc-treatment/from-the-editor/118198-primary-tumors-can-tell-us-more-if-we-ask-them-to.html
Apr 11, 2020
11
Response prediction of 177Lu-PSMA-617 RLT using PSA, Chromogranin A, and LDH.
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/116092-response-prediction-of-177lu-psma-617-rlt-using-psa-chromogranin-a-and-ldh.html
Apr 11, 2020
4
Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer.
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/119652-immunohistochemistry-based-assessment-of-androgen-receptor-status-and-the-ar-null-phenotype-in-metastatic-castrate-resistant-prostate-cancer.html
Apr 11, 2020
4
Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer.
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/110806-targeting-androgen-receptor-independent-pathways-in-therapy-resistant-prostate-cancer.html
Apr 11, 2020
1
The pitfall of the small cell prostate carcinoma variant resulting in a false-negative bone scan and choline PET/CT study in a case of prostate cancer, "Beyond the Abstract," by Ammad Al Tamimi MD, FRCR
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/71117-the-pitfall-of-the-small-cell-prostate-carcinoma-variant-resulting-in-a-false-negative-bone-scan-and-choline-pet-ct-study-in-a-case-of-prostate-cancer-beyond-the-abstract-by-ammad-al-tamimi-md-frcr.html
Apr 11, 2020
6
The role of lineage plasticity in prostate cancer therapy resistance.
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/114430-the-role-of-lineage-plasticity-in-prostate-cancer-therapy-resistance.html
Apr 11, 2020
5
Neuroendocrine Carcinomas of the Genitourinary Tract – Treatment Options Are Desperately Needed… Even During the COVID-19 Pandemic
www.urotoday.com/clinical-trials/from-the-editor/120311-neuroendocrine-carcinomas-of-the-genitourinary-tract-treatment-options-are-desperately-needed-even-during-the-covid-19-pandemic.html
Apr 11, 2020
1
Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer.
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/109736-neuroendocrine-differentiation-markers-guide-treatment-sequence-selection-in-metastatic-castration-resistant-prostate-cancer.html
Apr 11, 2020
3